In recent years, NPTX2 has been suggested to provide additional and independent prediction of the onset of mild cognitive impairment (MCI) in cognitively normal individuals, and it might serve as an important prognostic biomarker during preclinical AD [26]. This evidence concerns the gene NPTX2 and Alzheimer disease.